Certara Inc Dossier
Qualitative Analysis
Business overview
Certara, Inc. is the global leader in model-informed drug development (MIDD) and biosimulation software. The company provides specialized software and technology-driven services that create virtual patients and virtual trials to predict drug behavior, efficacy, and safety before human clinical testing. Certara's biosimulation solutions have supported over 90% of all novel drug approvals by the FDA since 2014, serving more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies globally. In April 2026, the company sharpened its strategic focus on core biosimulation and clinical intelligence by divesting its Regulatory and Medical Writing business to Veristat for up to $135 million.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the integration of artificial intelligence across Certara's product portfolio, highlighted by the deployment of the Certara IQ platform for Quantitative Systems Pharmacology (QSP) and AI-driven regulatory writing tools.
Expected impact: Improves modeling productivity, enhances data connectivity, and delivers higher-value automated solutions to biopharmaceutical clients.
Reorganizing the company's operations around two focused growth areas (Model-Informed Drug Development and Clinical Intelligence) while divesting non-core, lower-margin service lines.
Expected impact: Sharper strategic focus, improved revenue growth consistency, and a more balanced revenue mix (approximately 50% software and 50% services).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand Certara's capabilities in drug discovery and cheminformatics, providing an end-to-end platform from atomistic discovery through clinical development.
Financial impact: Contributed to software revenue growth and expanded the company's addressable market in early-phase discovery.
Strategic Partnerships
Integrates Certara's model-informed drug development (MIDD) and biosimulation capabilities directly into Altasciences' early-phase clinical trial execution platform.
Terms: Not publicly disclosed